BioCentury
ARTICLE | Clinical News

Poxel, Sumitomo launch Phase III program of imeglimin in diabebetes

January 5, 2018 10:58 PM UTC

Poxel S.A. (Euronext:POXEL) and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) began the double-blind, placebo-controlled, 24-week Japanese Phase III TIMES I trial of imeglimin (PXL008) to treat Type II diabetes. It is the first of three trials in the Phase III TIMES program, which will enroll a total of about 1,100 patients.

TIMES 1 will evaluate twice-daily oral 1,000 mg imeglimin in more than 200 patients. The primary endpoint will measure change in HbA1c. Secondary endpoints include other undisclosed standard glycemic and non-glycemic parameters...